CN104419677A - Construction of trisomy 18 syndrome cell model and cell bank thereof by hTERT transgenosis - Google Patents
Construction of trisomy 18 syndrome cell model and cell bank thereof by hTERT transgenosis Download PDFInfo
- Publication number
- CN104419677A CN104419677A CN201310407555.3A CN201310407555A CN104419677A CN 104419677 A CN104419677 A CN 104419677A CN 201310407555 A CN201310407555 A CN 201310407555A CN 104419677 A CN104419677 A CN 104419677A
- Authority
- CN
- China
- Prior art keywords
- cell
- htert
- trisomy
- growth
- model
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 title claims abstract description 7
- 238000010276 construction Methods 0.000 title abstract 3
- 230000012010 growth Effects 0.000 claims abstract description 35
- 238000011160 research Methods 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 21
- 239000013612 plasmid Substances 0.000 claims abstract description 18
- 238000000338 in vitro Methods 0.000 claims abstract description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000003321 amplification Effects 0.000 claims abstract description 14
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 14
- 238000012360 testing method Methods 0.000 claims abstract description 13
- 230000001413 cellular effect Effects 0.000 claims abstract description 10
- 230000007774 longterm Effects 0.000 claims abstract description 10
- 238000001638 lipofection Methods 0.000 claims abstract description 9
- 241000699660 Mus musculus Species 0.000 claims abstract description 8
- 238000011580 nude mouse model Methods 0.000 claims abstract description 8
- 238000012216 screening Methods 0.000 claims abstract description 8
- 230000006907 apoptotic process Effects 0.000 claims abstract description 7
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 7
- 230000008506 pathogenesis Effects 0.000 claims abstract description 7
- 208000005623 Carcinogenesis Diseases 0.000 claims abstract description 6
- 238000012408 PCR amplification Methods 0.000 claims abstract description 6
- 230000036952 cancer formation Effects 0.000 claims abstract description 6
- 231100000504 carcinogenesis Toxicity 0.000 claims abstract description 6
- 108010017842 Telomerase Proteins 0.000 claims abstract description 5
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims abstract description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims abstract description 4
- 238000001502 gel electrophoresis Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 293
- 208000037280 Trisomy Diseases 0.000 claims description 50
- 210000000349 chromosome Anatomy 0.000 claims description 19
- 235000015097 nutrients Nutrition 0.000 claims description 19
- 238000012258 culturing Methods 0.000 claims description 18
- 238000011534 incubation Methods 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 11
- 230000010261 cell growth Effects 0.000 claims description 11
- 230000029087 digestion Effects 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 10
- 239000006285 cell suspension Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 230000001464 adherent effect Effects 0.000 claims description 7
- 244000309466 calf Species 0.000 claims description 7
- 238000002474 experimental method Methods 0.000 claims description 7
- 238000012797 qualification Methods 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 239000012679 serum free medium Substances 0.000 claims description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
- 102000029816 Collagenase Human genes 0.000 claims description 6
- 108060005980 Collagenase Proteins 0.000 claims description 6
- 229960002424 collagenase Drugs 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 6
- 230000008676 import Effects 0.000 claims description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 229960001338 colchicine Drugs 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 230000003950 pathogenic mechanism Effects 0.000 claims description 3
- 206010053884 trisomy 18 Diseases 0.000 claims description 3
- 201000006360 Edwards syndrome Diseases 0.000 claims description 2
- 210000004381 amniotic fluid Anatomy 0.000 claims description 2
- 201000003738 orofaciodigital syndrome VIII Diseases 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims 1
- 238000012151 immunohistochemical method Methods 0.000 claims 1
- 238000001890 transfection Methods 0.000 abstract description 14
- 108020004414 DNA Proteins 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 238000000605 extraction Methods 0.000 abstract description 4
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 229960000723 ampicillin Drugs 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 238000001976 enzyme digestion Methods 0.000 abstract 1
- 238000003364 immunohistochemistry Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 28
- 239000000243 solution Substances 0.000 description 25
- 238000003908 quality control method Methods 0.000 description 18
- 230000007547 defect Effects 0.000 description 15
- 239000000523 sample Substances 0.000 description 14
- 238000001962 electrophoresis Methods 0.000 description 10
- 238000001556 precipitation Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 101000965899 Simian virus 40 Large T antigen Proteins 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 231100000167 toxic agent Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102100031780 Endonuclease Human genes 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000000877 Sex Attractant Substances 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 210000002593 Y chromosome Anatomy 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000013441 quality evaluation Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 208000011359 Chromosome disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 108010020437 Ki-67 Antigen Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010027543 Micrognathia Diseases 0.000 description 1
- 208000002598 Micrognathism Diseases 0.000 description 1
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 1
- 208000005289 Neoplastic Cell Transformation Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 201000009928 Patau syndrome Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 1
- 102000052708 Recessive Genes Human genes 0.000 description 1
- 108700005079 Recessive Genes Proteins 0.000 description 1
- 102000016941 Rho Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 108010053823 Rho Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000017064 TORCH syndrome Diseases 0.000 description 1
- 206010044686 Trisomy 13 Diseases 0.000 description 1
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000000250 cementoblast Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000024971 chromosomal disease Diseases 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000005770 chromosome separation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000002986 dental sac Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009985 maternal smoking Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000004540 pour-on Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 238000009609 prenatal screening Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 238000001963 scanning near-field photolithography Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to construction of an hTERT mediated trisomy 18 syndrome cell model and a cell bank thereof in the medical field. The construction is mainly characterized in that incision enzymes EcoR I and Xho I are used for carrying out double enzyme digestion on plasmid pCIneo-hTERT and carrier pLXSNneo, and Ligation Mix is used for connecting hTERT and pLXSNneo enzyme-digested products subjected to PCR amplification and gel electrophoresis separation to construct a pLXSNneo-hTERT recon; DH5a competent cells are transformed to purify, amplify and pick ampicillin-resistant bacterial colony extraction plasmids; trisomy 18 syndrome cells in logarithmic growth during in-vitro passage are subjected to lipofection transfection; the recons are integrated with cell DNAs and are subjected to amplification culture; positive recon colons are subjected to G418 screening; cells, which meet the immortalized cell characters in the aspects of cellular morphology, growth curve, karyotype, nude mice tumorigenesis test, transfected cell telomerase activity, hTERT mRNA expression, immunohistochemistry, and cell generation cycle and apoptosis rate and are as same as or similar to primary cells, are screened to be as the hTERT mediated trisomy 18 syndrome external research cell models to be frozen in liquid nitrogen. Therefore, the foundation of in vitro long-term research of pathogenesis of trisomy 18 syndrome based on the cellular level is established.
Description
Technical field
The present invention relates to hTERT (reverse transcriptase of telomere catalytic subunit) transgenosis (mediation) and build E trisomy cell model and cell bank thereof, be mainly used in Newborn Birth-defects intervention study field, the in vitro study for E trisomy provides cell model and preserves its Scientific Research Resource.
Background technology
E trisomy belongs to one of great inborn defect, also name Edward's syndrome, namely patient is many No. 18 karyomit(e)s, this syndrome cardinal symptom shows as that patient's head has rear convex occipitalia, palpebral fissure is narrow and small, ear is lopsided, ear position low, micrognathia, breastbone are short and small.Because infant exists serious mental retardation companion Poly-monstrosity, 50% is dead in 2 months after birth, can live to 1 year less than 10%, can live 15 years old extremely individually.For want of effective treatment means, once infant birth brings spirit and economical load greatly will to family and society, has had a strong impact on the quality of the people of China, has become the heavy burden of social development and the serious hindrance of Sustainable development.
In recent years, E trisomy is classified as one of great inborn defect both at home and abroad, intervenes object as emphasis, and establish Prenatal Screening and methods for prenatal diagnosis.Emphasize in " 11th Five-Year Plan outline of national economy and social development ", the Intervention density of the inborn defects such as E trisomy be strengthened, to improve the health of newborns; In " National Program for Medium-to Long-term Scientific and Technological Development (2006-2020) ", the research of the inborn defects such as E trisomy is classified as preferential theme.
At present to the research of the inborn defects such as E trisomy mainly for the relation of heredity, biology, physics, chemical factor and morbidity (rate) and its early screening and diagnosis aspect, as there being a large amount of bibliographical informations abroad, the environmental factorss such as the generation of the inborn defects such as 18-tri-body and provincialism, Time to pregnancy, nuisance contact history are significant correlation; Have foreign literature to report, two identical recessive genes existing during consanguineous mating are relevant with giving birth to the inborn defect infants such as E trisomy; The body weight of the report such as Graaf, Rudnicka pregnant woman, smoking habit, final recognition are relevant with E trisomy screening indexes; The inborn defects such as Maternal Smoking Smoking, trace element, psychological factor, diet, torch infection etc. and E trisomy are relevant separately to have domestic scholars to report.
But, due to do not have can in vitro long-term cultivation, the immortality cell model that can be used for study of incident mechanism and cell bank thereof, just be difficult to study from cell levels the mechanism such as transgenation, genetic expression, changing function, physiological property, biology conduction that E trisomy cell affects by physics, chemistry, biology, heredity etc. in vitro, thus seriously limit the further research of E trisomy.
Foreign literature is reported, simian virus 40 (SV40) can make some human cell that immortalization occurs.The research such as Poulin DL, Kung AL and Sullivan CS shows, the importing of SV40T antigen gene can accelerate the growth velocity of transformant, after immortalized cells repeatedly goes down to posterity in vitro, still there is metastable multiplication characteristic and functional status, also can retain many phenotypic differentiations of its initiating cell simultaneously, may be used for the foundation of the cell model of transgenic animal model and some kind of human and animal, the characteristic of initiating cell can be studied accordingly by means of research transgenosis immortalized cells and animal model in vitro, thus study its pathogenesis.
But studies have found that recently, the cell of simian virus 40 large T antigen (SV40Tag) transfection is along with the loss of DNA damage repair mechanism, the unstable of caryogram and a few cell neoplastic transformation.In addition; long-term in vitro is cultivated and is found that the cell of part transfection SV40Tag just extends the life-span; or only tided over senescence phase (MI phase), part cell finally can enter climacteric (M2 phase) and dead, and cell being not immortalized is described.Simultaneously SV40 virus has tumorigenicity, and with the generation of some tumour, develop relevant, it is restricted that the cell of therefore SV40Tag transfection also exists to a certain degree to some research.
Foreign study shows, imports exogenous hTERT and cell can be made to keep normal phenotype and differentiating characteristic.Utilized hTERT successfully to establish the immortalized cell line of some cell in recent years, substantially kept that chromosome stabilityX, differentiation are normal, contact inhibition, growth characteristics without relative " normally " such as tumorigenicity.May be used for the foundation of the cell model of some kind of human and animal, to the characteristic studying initiating cell by means of research transgenosis immortalized cells model, thus study its pathogenesis, have great importance.
In stomatology field, Japanese scholars Kamata, Fujita and Fujii transfection hTERT establishes immortal human Gingival Fibroblasts, periodontal cell, pulp cells system and Dental Follicle Cells system, cell population doublings number reaches more than 150 times, cell all shows original biological characteristics, can express the associated protein of derived cell after inducing culture.The transfection hTERT such as Kitagawa establish people cementoblast system, and cell multiplication reaches more than 200 times, and cytodifferentiation mark such as alkaline phosphatase, type i collagen etc. are expressed stable.Because of the needs of research work, almost often kind of disease has respective cell model.As diabetes cell model, cancer cell model, transgenic cell model, climacteric syndrome cell model, endometrial cell model, epilepsy cell model, E-Cell models, alcoholic dementia cell model, cerebral edema cell model.Etc..
But, there is not yet so far and be used in the external bibliographical information studying the pathogenetic immortality cell model of E trisomy and cell bank thereof from cell levels about building with hTERT, also cannot carry out the research of relevant item.In order to solve the problem, present inventors have proposed the present invention.
Summary of the invention
The object of the invention is to provide the method building E trisomy cell model and cell bank thereof with hTERT (reverse transcriptase of telomere catalytic subunit) transgenosis (mediation), another object is for providing hTERT to mediate E trisomy cell model and cell bank thereof from the pathogenesis of cell levels research E trisomy in vitro.
The object of the present invention is achieved like this: with restriction endonuclease EcoR I and Xho I double digestion plasmid pCIneo-hTERT and carrier pLXSNneo, connect through pcr amplification with Ligation Mix, hTERT and the pLXSNneo digestion products that gel electrophoresis is separated, build pLXSNneo-hTERT recon, transform DH5a competent cell with amplification, purifying the picking bacterium colony of resistance to penbritin extracting plasmid, the E trisomy cell gone down to posterity in logarithmic growth is imported in vitro with lipofection, the DNA of recon and cell is integrated, and the clone of positive recombinant that enlarged culturing is screened through G418, screening cellular form, growth curve, karyotype, nude mice tumorigenesis is tested, transfectional cell telomerase activation, hTERT mrna expression product, immunohistochemical staining, cell generation cycle and apoptosis rate meet immortalized cells characteristic and identical with primary cell or close person to mediate E trisomy in vitro study cell model as hTERT frozen in liquid nitrogen, for the pathogenesis of the E trisomy that studies for a long period of time in vitro from cell levels lays the foundation.
The present invention is with pcr amplification, agarose gel electrophoresis purification hTERT, import E trisomy cell through genophore pLXSNneo and lipofection and build its cell model, its histocyte digest with 0.01% collagenase II and need not be conventional tryptic digestion, digested or make cell suspension with the collagen only making to cause cytoadherence, the protein decreasing cell walls is digested and injure cell, makes the success ratio of cell cultures bring up to more than 95% by general about 85%; Select the defined medium containing 20mL/L foetal calf serum, 5 ~ 10nmol/L Regular Insulin, make cell can not grow too fast and affect the integration of hTERT gene, also can not make because lacking nutrition or Growth of Cells stimulating factor cell do not meet the requirements of converge rate, do not enter logarithmic phase before with regard to premature death, or logarithmic phase shortens; Clone recovery cultivation after frozen 1 month in-196 DEG C of liquid nitrogen of preparation, all can grow attached cell; When making clone Chromosome Identification, the consumption of colchicine and action time are conventional 5 ~ 10 times, and chromosome separation is increased mutually, are enough to counting and analyze; In addition; compared with SV40; building cell model with hTERT more can make cell keep normal phenotype and differentiating characteristic; more can keep that chromosome stabilityX, differentiation are normal, contact inhibition, without tumorigenicity and tide over the growth characteristics such as M2 climacteric, to the pathomechanism studying E trisomy from cell levels in vitro, there is larger meaning.
Accompanying drawing explanation
Fig. 1 is 18 Trisomy cell model (adherent growth) figure prepared by the present invention.
As Fig. 1, passage to the 67th generation, be cultured to the 10th day time, in logarithmic growth, circle, fusiformis, to be paved with bottle at the bottom of, its Growth of Cells converges rate and reaches more than 93%, and after this along with the increase of passage number, Growth of Cells is slack-off, thinning to be dredged.
Embodiment
1, the extraction of hTERT: 1. enzyme cuts pClneo-hTERT:hTERT between EcoRI and the SalI site of plasmid pClneo-hTERT, and pLXSNneo vector multiple cloning site (MCS) is containing EcoRI and XhoI restriction enzyme site.Commercially available purchase pCIneo-hTERT plasmid, is dissolved in appropriate ultra-clean H
2in O or TE damping fluid, add 2uL10 × enzyme cutting buffering liquid and 18uL H
2o, adds restriction enzyme EcoR I and each 0.5ul of Xho I, 37 DEG C of incubation 1h, 75 DEG C of heating 15min, inactivator, adds 5uL electrophoresis sample loading buffer (also by adding 0.5mol/LEDTA) termination reaction, routinely after PCR method amplification hTERT, collect amplified material in order to electrophoresis.2. hTERT electrophoresis: power taking swimming level agarose is made into 10% sepharose with electrophoretic buffer, pour on the gel casting platform sealed, plug sample comb, from glue platform removing envelope band after gelling is solid, extract comb, put into the electrophoresis chamber being added with enough electrophoretic buffers, damping fluid exceeds gel surface and is about 1mm, prepare hTERT enzyme with 10 appropriate × sample loading buffer and cut sample, then with pipettor, sample is added in sample well, and do suitable standard control thing simultaneously, connect electrode, hTERT anode is moved, under the voltage of 1-10V/cm (80V) gel, electrophoresis is to (30min) during the distance of enough separation hTERT fragments, powered-down.3. hTERT purifying and recovery: be separated hTERT band from agarose: under long wave ultraviolet light source, the gel-tape containing target hTERT fragment is cut and load in dialysis tubing, 2ml electrophoretic buffer is added in dialysis tubing, make it submergence gel, and emptying steam bubble, dialysis tubing level is put into electrophoresis chamber (length direction is parallel with electrophoresis), add appropriate amount of buffer solution by dialysis tubing submergence (about 6-7mm), switch on power, 150 volts of electricity are washed, observe under ultraviolet lamp and treat that hTERT all shifts out gel, change direction of an electric field and continue energising 1 minute, from dialysis tubing, sucking-off damping fluid is in 1-5ml Eppendorf pipe, add 1.5 times of volume propyl carbinols, EB is removed in mixing extracting, on desk centrifuge 2 minutes the most at a high speed, suck upper strata butanol solution, repetition secondary like this, equal-volume phenol chloroform (2) extracting 2 times is added in the solution of lower floor hTERT, supernatant proceeds in another Eppendorf pipe and adds 1/10 times of volume 3M NaAc, 2 times of volume precooling dehydrated alcohols, spend the night in 20 DEG C, 12000g, at 4 DEG C centrifugal 10 minutes, obtain hTERT precipitation, abandon supernatant, dry ethanol is abandoned after adding 70% washing with alcohol 2 times, add 50 μ lTE and dissolve hTERT.In addition, also object hTERT fragment is separated, is purified by available low melting-point agarose gel method, hTERT filter membrane inserted sheet method etc. from gel.
2, the connection of hTERT and pLXSNneo carrier: get the hTERT composition (0.1-5 μ g) of the above-mentioned purifying of 9 μ l, 1 μ l10mmol/L ATP, 10ul Ligation Mix or e. coli dna ligase, the mixing of 2ul pLXSNneo empty carrier, 15 DEG C of incubation 24h, build pLXSNneo-hTERT recon.
3, the purifying of pLXSNneo-hTERT recon, amplification, qualification: the 1. preparation of E. coli competent: its basic skills is ice-cold CaCl
2or the process such as multiple divalent positively charged ion bacterium, making it to enter competence is transformed, and uses CaCl
2prepare fresh or freezing competent escherichia coli cell, be usually used in preparation in quantity competence bacterium, this law is applicable to most of coli strain, operating process is summarized as follows: cultivate picking single bacterium colony (as bacillus coli DH 5 2) the fresh plate of 16 ~ 20h from 37 DEG C, or 16 ~ 20h overnight culture that 1ml is fresh, forward one to containing in 1L or the 500ml flask of 100mlLB substratum, about 2 ~ 3h (rotary shaker 200 ~ 300r/min) is cultivated in 37 DEG C of violent joltings, OD600 value ≈ 0.4 is measured every 20 ~ 30min, aseptically bacterium is transferred to one, in ice-cold 50ml polypropylene centrifuge tube, 10 ~ 20min is placed on ice, in 4 DEG C with SorvallGS2 rotary head (or the rotary head matched with its centrifuge tube) with the centrifugal 10min of 4000r/min, to reclaim cell, nutrient solution reciprocal, pipe is inverted 1min to flow to end to make the trace nutrient solution of final residual, with the ice-cold 0.1mMCaCl of 10ml
2resuspended every part of precipitation, be put on ice, in 4 DEG C with SorvallGS3 rotary head (or its corresponding rotary head) with the centrifugal 10min of 4000r/min, to reclaim cell, pour out nutrient solution, pipe is inverted 1min to flow to end to make the trace nutrient solution of final residual, the 0.1M CaCl of every 50ml initial incubation thing 2ml ice precooling
2resuspended every part is sunk calmly, and now, rapidly cell can be distributed into aliquot, freezing in liquid nitrogen ,-70 DEG C of storages are for subsequent use.2. with competence intestinal bacteria purifying, amplification pLXSNneo-hTERT recon: get 200 μ l with the sterile pipette tip cooled from every kind of competent cell suspension and transfer in aseptic Eppendorf tube, often pipe adds DNA or ligation mixture (volume≤10 μ l, DNA≤50ng), rotate gently to mix content, 30min is placed in ice, centrifuge tube is put into pre-heating on the test-tube stand in the circulator bath of 40 DEG C, place 90s ~ 2min, do not shake test tube, fast pipe is transferred in ice bath, cell is made to cool 1 ~ 2min, every centrifuge tube adds 800 μ lSOC substratum, with water-bath, substratum is warmed to 37 DEG C, then pipe is transferred on 37 DEG C of shaking tables, incubation 45min makes bacteria resuscitation, and antibiotic-resistance marker's gene of expression plasmid coding, the competent cell that proper volume (every 90mm flat board can reach 200 μ l) has transformed is transferred to containing on 200mmol/LMgSO4 and corresponding antibiotic SOB substratum, flat board is placed in room temperature to be absorbed to liquid, be inverted plate, in 37 DEG C of cultivations, bacterium colony can be there is after 12 ~ 16h.3. screen, increase recon: select single colony inoculation in the aseptic LB substratum of 5mL or rich medium (as super broth or TB super broth substratum) with sterile toothpick or disinfection inoculation pin, after overnight incubation, join 500mL again containing in the 2L flask of LB substratum (containing suitable microbiotic), then be cultured to state of saturation (OD in 37 DEG C
600≈ 4, for improving output, the flask of the comparatively large and band traverse baffle of surface-area should be adopted to increase venting quality as far as possible, jolting speed should be greater than 400r/min), in 4 DEG C, the centrifugal 10min of 6000g, by the resuspended precipitation of 4mL GTL solution, and transfer to (bacterial precipitation can be preserved at-20 DEG C or-70 DEG C of indefinitely) in the high speed centrifugation pipe of a volume>=20mL, add the GTE solution containing 25mg/mL N,O-Diacetylmuramidase that 1mL newly joins, resuspended precipitation, 10min is placed in room temperature, add 10mL and newly join NaOH/SDS solution, and mixing is until liquid becomes homogeneous gently, limpid and thickness, in placing 10min on ice, add 7.5mL acetic acid solution, stir until viscosity declines and forms large precipitation gently with suction pipe, in placing 10min on ice, in 4 DEG C, the centrifugal 10min of 20000g, supernatant is poured into gently in another clean centrifuge tube, if there is visible drift can by several layers of filtered through gauze, add the Virahol of 0.6 times of volume, put upside down mixing, room temperature places 5 ~ 10min, in room temperature, the centrifugal 10min of 1500g, add the washing precipitation gently of 2mL70% ethanol, then of short duration centrifugal fast, suck ethanol, and vacuum-drying (precipitation can be preserved for a long time at 4 DEG C).4. the qualification of recombinant plasmid and amplification: the single bacterium colony on picking plate, be inoculated in 3ml containing in 100ug/ml penbritin LB substratum, 37 DEG C, cultivate in 250r/min shaking table, culture is collected after 14h, 4 DEG C, the centrifugal 5min of 10000r/min, extract and purification of Recombinant plasmid in a small amount by test kit specification sheets; With EcoRI and HindIII double digestion recombinant plasmid reaction system: each 0.5ul of restriction enzyme, 10 × buffer2ul, recombinant plasmid 10ul, adding water complements to 20ul, 37 DEG C of enzymes cut 1h.Digestion products carries out 0.8% agarose electrophoresis under 80V voltage conditions, time 30min, and gel imaging system is taken pictures; Measure the sequence of recombinant plasmid routinely; Recombinant plasmid is cut through enzyme, after qualification accurately of checking order, by the microbionation containing this plasmid in LB nutrient solution, amplification cultivation, carries out heavy dose of plasmid extraction purifying by heavy dose of plasmid extraction test kit specification sheets, and ultraviolet spectrophotometer is for subsequent use after measuring plasmid concentration and purity.
4, pLXSNneo-hTERT recon imports the screening of E trisomy cell and positive colony thereof: the 1. collection of E trisomy cell and cultivation: be extracted in aseptic technique and do other and test or other check unnecessary, the E trisomy infant amniotic fluid cast-off cells discarded afterwards, be about 1 × 10 with final concentration of cells
5/ mL is for subsequent use, the cell got above-mentioned cell in single dispersion or become single dispersion is after treatment inoculated in containing 5 ~ 10nmol/L Regular Insulin, in the RPMI1640 liquid of 20% foetal calf serum or be inoculated in containing 20% foetal calf serum, in the low sugar DMEM cell culture medium of 5 ~ 10nmol/L Regular Insulin, be placed in 37 DEG C, in volume fraction 5%CO2 incubator, cell attachment is cultivated about 3 ~ 4 days, cellular form is fusiformis, little circular cell is less than 10%, the rate of converging of attached cell reaches 75% ~ 85%, be in when just entering logarithmic phase, namely consider to collect culturing cell, first blot the nutrient solution in clean culturing bottle, add collagenase II liquid or the pancreatin (can cover at the bottom of whole bottle with Digestive system and be as the criterion) of 1-2ml0.01%, leave standstill 2-10min (under microscope dynamic monitoring), suck collagenase II liquid, add low sugar DMEM or RPMI1640 nutrient solution, draw culture in glassware liquid, repeatedly blow and beat bottle parietal cell, form cell suspension, proceed to centrifuge tube centrifugation, remove supernatant liquor, after cell precipitation cleans 2 times with above-mentioned nutrient solution, make suspension, import as recon.2. the importing of pLXSNneo-hTERT recon: method 1: in upper method Isolated cells, select lipofection, by above-mentioned 2 × 10
5individual cell is inoculated in 35mm culture dish, at 37 DEG C of CO
224 ~ 36h cultivated by incubator, make Hemapoiesis individual layer, form be fusiformis, there is not yet or be rarely seenly less than 10% little circular cell, the rate of converging of attached cell reaches 55% ~ 65%, is in when entering or just entered logarithmic phase, namely transfection recon pLXSNneo-hTERT is considered, in 1.5ml Eppendorf tube, prepare following solutions: pipe A, pLXSNneo-hTERT recon is dissolved in 100 μ l serum-free mediums; Pipe B, 20 μ l Lipofectamine are dissolved in 80 μ l serum-free mediums, mixed by pipe A and pipe B, the underlying 45min of room temperature, after sucking cell culture fluid, with serum-free medium washed cell 2 times, in Lipofectamine-pLXSNneo-hTERT mixture, add 1ml serum-free medium, mix gently, then drop in Tissue Culture Dish, then 1ml serum-free medium is added, at CO
210h cultivated by incubator, sucking-off transfection liquid, and add 4ml complete culture solution and continue to cultivate 16h, discard nutrient solution, changing concentration is 400mg ° of L
-1g418 nutrient solution continue to cultivate, within 8 ~ 10 days, select individual cells colony to carry out subclone afterwards, strengthen G418 concentration after enlarged culturing again to 800mg ° of L
-1, in the G418 environment of high density, amplification of going down to posterity can be carried out by the clone of stable growth.Method 2: draw 1/10-1/40 cell suspension, being mixed with final concentration is 1 × 10
5/ mL cell suspension, be inoculated in culturing bottle, select low sugar DMEM or RPMI1640 substratum, wherein containing 20mL/L foetal calf serum, 10nmol/L Regular Insulin, after cultivating 48h, make Hemapoiesis individual layer, cellular form is fusiformis, there is not yet or rarely seenly be less than 10% little circular cell, attached cell converges rate and reaches 55% ~ 65%, be in when will enter or just enter logarithmic phase, adopt the method for liposome transfection, by recon pLXSNneo-hTERT transfection in E trisomy cell, with the liquid medium-selection 1wk containing 700mg/L G418, change G418 concentration into 300mg/L, to occurring positive colony, transfer them to new culturing bottle to expand, Secondary Culture, method 3: above-mentioned cell suspension is made into 5 × 10 with low sugar DMEM or RPMI1640 nutrient solution
8the cell suspension inoculation of/L final concentration in 24 well culture plates, until cell grow to about 90% merge time for transfection, by the recon pLXSNneo-hTERT of 0.2 μ g content, with DMEM or RPMI1640 adjust volume be 50 μ l, room temperature place 5min, liposome 6 μ l, adjusting volume with DMEM is 50 μ l, room temperature places 5min, two kinds of reagent mix gently, room temperature places 20min, cell DMEM in 24 orifice plates is washed 3 times, every hole adds nutrient solution 100 μ l, adds Lipofectamine-pLXSNneo-hTERT mixed solution, gently cell surface paving evenly, 6h is placed in 37 DEG C of CO2 incubators, use 0.01g/L collagenase by cell dissociation subsequently, proceed in 6 orifice plates, add perfect medium, adding G418 microbiotic next day makes final concentration be 500mg/L, until there is monoclonal cell to grow.Have monoclonal cell colony to grow after about 10d, picking is also placed in continuation cultivation in 24 orifice plates, maintains and stabilize with the G418 of 300mg/L the amplification cultivation that goes down to posterity.E trisomy cell model is built with this.
5, the going down to posterity of pLXSNneo-hTERT transfection E trisomy cell model, increase: collect the above-mentioned positive monoclonal cell colony importing pLXSNneo-hTERT through lipofection, be made into about 1 × 10 with low sugar DMEM or RPMI1640 substratum
5the cell suspension of/mL, is inoculated in several bottles of 20 ~ 50cm
2in culturing bottle, add 5mL containing 20mL/L foetal calf serum, the low sugar DMEM of 10nmol/L Regular Insulin or RPMI1640 substratum, to cell attachment growth, converge rate reach 80 ~ 85%, be in the early stage of logarithmic phase time collecting cell, again by above-mentioned steps Secondary Culture, inoculation of repeatedly going down to posterity like this, cultivation, record algebraically and observation of cell growth characteristic.As Fig. 1, passage to the 67th generation, be cultured to the 10th day time, in logarithmic growth (cell growth rate is directly proportional to incubation time), circle, fusiformis, to be paved with bottle at the bottom of, its Growth of Cells converges rate and reaches more than 93%, after this along with the increase of passage number, Growth of Cells is slack-off, thinning to be dredged.Wherein logarithmic growth refers to high cell growth speed, and the increase of cell quantity and incubation time are multiplication relation, when usually cultivating by kind of a cell routinely, cultivates the individual cells that just can find growth for 1 ~ 2 day under the microscope; Visible cell colony when 4 ~ 5 days, at the bottom of adherent growth cell bedding culturing bottle 1/3, at the bottom of visible adherent growth cell bedding culturing bottle more than 2/3 when cultivating 7 ~ 13 days, even cell overlap, interspace hardly (converge rate and reach 95 ~ 100%), cell light, without particle, without catabiosis such as harsh feelings, also can judge according to the relation of cell counting and incubation time; Dead cell is few, and cause death and floating cell are less than 10% [differentiate dead cell and viable cell by trypan blue staining, because normal viable cell, after birth structural integrity, can repel, and trypan blue can not be entered in born of the same parents weekly; And the cell of loss of activity, the permeability of after birth increases, blueness can be dyed by trypan blue, can be judged as that cell is dead, method draws weekly a certain amount of suspension culture, mixes rearmounted room temperature 5 ~ 10 minutes, then make cell sheet with Trypan Blue agent, count 1000 total cellular score under the microscope, calculate the per-cent of painted dead cell and non-staining viable cell].
6, the qualification of E trisomy cell model biological characteristics: after using pLXSNneo-hTERT to set up cell model, the key issue of qualification has: is that this cell of requirement has lasting multiplication capacity; Two are its forms of requirement, basic physiological function isophenous remains unchanged.Whether 1. observation of cell form: every day, whether observation of cell was in typical epithelial cell sample adherent growth under inverted light microscope is fusiformis or the growth of little circular.This clone goes down to posterity the cellular form of amplification cultivation and Normal human fibroblast's form no significant difference; 2. observation of cell growth curve: get the good transfectional cell of growth, adopts 0.25 trypsin solution digestion, makes cell suspension, through counting, get 1.4 × 10 respectively
4cell is inoculated in 30 containing 15FBS low sugar DMEM culture medium culturing bottle.Get 2 bottles of cells every day to count, computation of mean values, Continuous Observation, until cell quantity obviously declines, is cultivated after 3 days and was changed liquid every 2 days to the cell of no count, adopts same method to observe the growing state of transfectional cell in hepato ZYME-SFM serum free medium.Result take incubation time as transverse axis, and cell quantity is the longitudinal axis (logarithm), be depicted in semi-logarithmic scale to make after curve the growth curve of this cell, immortalized cell line is formed in typical " S " feature or " arched roof "; 3. karyomit(e) is checked: if karyotype is 47, XX ,+18; Or 47, XY ,+18; Or be same as the primary 18 Trisomy cells of the present invention's collection, then illustrate that this clone vicious transformation does not occur and (whether occurs abnormal DNA colony in available flow cytometry analysis clone simultaneously, if no, also illustrate that knurl feature does not appear in clone).Chromosome karyotype analysis method is: reach 85-95% (its medium and small circular cell accounts for 10%) at cell density, to be in the culture of logarithmic phase in by 5mL nutrient solution the 250ug/ml colchicine 100ul adding preheating, mix rearmounted 37 DEG C of incubators 4 hours, blot nutrient solution, add the 2-3mL EDTA-trysinization liquid of preheating, 37 DEG C act on 5 minutes, stop digestion, wash lower attached cell, through centrifugal, hypotonic, fixing, film-making, G aobvious band post analysis karyotype; 4. soft agarose growth test: by cell with 5 × 10
4it is in 35mm soft agar plate that/ml is inoculated in diameter, after observing three weeks, does not find Clone formation, illustrates that the immortalized cells of this experiment can not form clone in soft agar, meets immortalization feature; 5. nude mice tumorigenesis test: by immortalized cells with 3 × 10
7inoculation nude mice dorsal sc, after 2 months, 4 nude mices are showed no tumour and are formed, and prove that this cell is non-malign cells; 6. transfectional cell hTERT mrna expression product measures: do pcr amplification rear electrophoresis by test kit, detect hTERT mRNA band.As with Immunohistochemical detection, in the nucleus of hTERT transfection, the visible a large amount of brown particle of dyeing, shows that hTERT has been integrated in cell; 7. transfectional cell telomerase activation: collecting cell system, illustrates by test kit and prepares lysate, does pcr amplification and electrophoretic analysis, with 302nm UV-light observations, visible in Telomerase positive band.8. Flow cytometry: the cell proportion detecting synthesis in the 19th continuous cell line, division, if its multiplication capacity obviously strengthens than not building the normal cell being, explanation is the result that hTERT integrates, expresses; In addition with Flow cytometry cell generation cycle and apoptosis rate, the Proliferating antigen Ki67 of this clone comparatively before and after transfection without obviously changing, Transfected cells apoptosis rate comparatively obviously reduces before transfection.
So cell model of the present invention is that 1. cell is the epithelial cell sample adherent growth of fusiformis or little circular under inverted light microscope; 2. the growth curve of cell is as taken incubation time as transverse axis, and cell quantity is the longitudinal axis, is that " S " feature or " arched roof " are formed in hepato ZYME-SFM serum free medium; 3. karyotype is 47, XX ,+18; Or 47, XY ,+18; 4. cell can not grow (forming clone) in soft agar; 5. cell is non-malign cells, nude mice tumorigenesis negative; 6. there is immortalization because incorporating hTERT gene in the DNA of cell, and express the mRNA product of hTERT; 7. passage to the 67th generation, be cultured to the 10th day time, in logarithmic growth, circle, fusiformis, to be paved with bottle at the bottom of, its Growth of Cells converges rate and reaches more than 93%; 8. can repeatedly freeze-thaw, Long Term Passages cultivate; 9. for studying the pathomechanism of Edwards syndrome; 10. the genetic resources of 18 heterotrimeric cell that hTERT integrates is preserved on recyclability ground.
7, hTERT mediates 18-patau syndrome cell model and cell bank thereof: screen and continue to go down to posterity, enlarged culturing meets immortalized cells characteristic and the cell identical or close with primary cell after above-mentioned qualification, get the attached cell that growth conditions is good, be in the different generations of logarithmic phase, through digestion, stop and centrifugation (1200r/min, 6min), with the frozen storing liquid 0.5 ~ 1ml re-suspended cell containing methyl-sulphoxide, cell density is 5 × 10
5individual/ml, adds cryopreservation tube packing, mark, through 4 DEG C, and 0.5h;-20 DEG C, 2h;-70 DEG C, spend the night, enter-196 DEG C of liquid nitrogen cryopreservations.Build the stable immortalization E trisomy cell model of biological characteristics and cell bank thereof in this way, with concentrated preservation genetic resources, for other researchs provide scientific research material, again can directly as the cell model of E trisomy pathogenesis in vitro study, to accelerate the new way expanding E trisomy research, study from cell levels the mechanism such as transgenation, genetic expression, changing function, physiological property, biology conduction that E trisomy cell affects by physics, chemistry, biology, heredity etc. in vitro.
8, cell model application
1) cell model is as scientific research cell: make 18 heterotrimeric cell models be in the artificial nuisance with different content or concentration manufactured as physics (as X-ray), chemistry is (as formaldehyde, gasoline, plumbous, mercury), biological (as rubella virus, cytomegalovirus, simplexvirus) condition under cultivate, then the viable cell of the different cycles of external Long Term Passages is got, the apoptotic cell of succeeding generations, nutrient solution containing the meta-bolites produced in Secondary Culture from different perspectives and level, research chromosome abnormalty, other are abnormal, normal control cells model is to the tolerance of nuisance, nuisance causes the mechanism of inborn defect.Such as apply ordinary method as gene chip, miRNA chip, comparative genomic hybridization hybrid chip (CGH), differential methylation hybridization hybrid chip (DMH) and SNPs, etc. screen the gene of difference and polymorphism, methylation level, the gene rate of rotation in the technology for detection gene place such as in situ hybridization (FISH), Northern blot, Real-time PCR, CHIP, EMSA research cell model is used to express, locate and regulation and control, utilize the meta-bolites of protein metabolism process and key in enzyme reaction, metabonomic technology identification of cell model Long Term Passages, application two-dimensional electrophoresis, MALDI-TOF Mass Spectrometric Identification, the protein function of the technical study such as yeast two-hybrid and co-immunoprecipitation cell model in Long Term Passages and the interaction between protein, dynamic from viable cell culturing process, the bad environmental factor that studies for a long period of time causes the mechanism of inborn defect, such as: 1. common in environment toxicant benzopyrene causes the research of 18 3 body inborn defects: make 18 heterotrimeric cell models and normal control cells contain 0.1 respectively, 1.0, 5.0, 10.0, cultivate in the nutrient solution of 20.0pmol/L benzopyrene, detect cultivation 2 weeks, 4 weeks, 6 weeks, 8 weeks, the apoptosis that can be used as cytotoxicity index of the different incubation time such as 16 weeks, downright bad, dikaryocyte rate and the micronuclear rates that can be used as genetoxic index, caryoplasm bridge rate, core bud rate, namely the micronucleus number in 10000 dikaryocytes is counted under an optical microscope, caryoplasm bridge number and core bud number, necrosis and apoptosis cell count in 500 viable cell, dikaryocyte number, and detection cell survival rate, namely tetrazolium-based colorimetric assay (mtt assay) is applied, after sucking original fluid, 96 orifice plates add the serum-free medium of the 5mg/mlMTT of 20%, continue to cultivate 4h, supernatant liquor in hole is abandoned in careful suction, every hole adds 150 μ L methyl-sulphoxides, vibration 10min, purple crystal thing is fully dissolved, and this microplate reader measures the absorbance in each hole with 490nm, calculates cell survival rate.Can also other normal experiment methods detect different incubation time containing toxic substance with containing the transgenation, proteomics, emiocytosis function, chromosome aberration, cell survival rate (life-span) etc. of respectively organizing cell in toxic substance, case and normal cell, with from viable cell culturing process from the mechanism that cell levels is dynamic, the bad environmental factor that studies for a long period of time causes 18 3 body inborn defects.2. replace toxicant benzopyrene with certain sex pheromone and do same research, can from the mechanism that cell levels is dynamic, the biotic factor that studies for a long period of time causes 18 3 body inborn defects from viable cell culturing process.3. by the medicine being made into concentration gradient be made into the sex pheromone of concentration gradient or poisonous chemical substance and 18 heterotrimeric cell model co-cultivation, can from viable cell culturing process from cell levels dynamically, the medicine that studies for a long period of time is to causing the result for the treatment of of 18 3 body inborn defect factors and the intervention effect to inborn defect.4. the method for available equally 18 heterotrimeric cell model research gene therapies, substitutes some and directly does experiment with human body.
2) cell model is as Quality Control cell: the quality control in laboratory is the access system of carrying out laboratory diagnosis project, becomes action by government.18 heterotrimeric cell models can be used as Quality Control cell, comment for Internal Quality Control and room interstitial.The chromosomal disorder laboratory diagnostic methods of clinical samples is such as synchronized with cell model, make regular growth cultivation, karyomit(e) preparation, chromosome karyotype analysis, to examine the reagent quality, instrument performance, working method etc. of experimentation whether reliable, be equivalent to the positive, the negative control in testing; By cell model after the image that routine chromosome preparation, chromosome karyotype analysis obtain arranges, each laboratory can be sent to, to examine each room to the accuracy of the diagnosis of various chromosome abnormalty image; Cell model can be sent to each laboratory, Result after each room makes regular growth cultivation, chromosome sectioning, chromosome karyotype analysis voluntarily, External quality evaluation is done to the diagnostic result of each room, by appraising through comparison the accuracy of each room, to find associated problem, deal with problems, to improve quality of diagnosis; 18 heterotrimeric cell models can be mixed in the kind required for Quality Control and ratio with various normal dyeing somatocyte, make the mixing Quality Control cell containing different sorts and ratio, numerical abnormalities of chromosomes Internal Quality Control cell is detected and room interstitial comments cell as fluorescence in situ hybridization (FISH), if certain laboratory is being done not detect different types of chromosome abnormalty of (failing to pinpoint a disease in diagnosis) Quality Control cell in FISH, accurately do not detect the ratio (%) of different types of chromosome abnormalty, then there are quality problems in illustrative experiment method, and reason should be looked for correct.Now be described as follows with the example that has particular application as of Quality Control cell in fluorescence in situ hybridization room interstitial is commented of preparation after the mixing of several chromosome abnormalty cell model: 1. prepare Quality Control cell: get 1 example or numerical example 18 3 body and karyomit(e) normal cell model, mix Quality Control cell in the example required for Quality Control time or ratio, the Quality Control cell of mixing also can use through amplification after discharge.As mixed with 1 routine karyomit(e) normal cell model equal proportion cell count with 1 example 18 3 Autosome number abnormal cells model, then the cell of 18 3 Autosome number exceptions and karyomit(e) normal cell respectively account for 50%.Then Quality Control cell is sent to each study subject and does External quality evaluation.2. fluorescence in situ hybridization (FISH) detects Quality Control cell chromosome number and result judgement: after each study subject receives Quality Control cell, and can going down to posterity to Quality Control cell strain as one sees fit, amplification is rear to be tested, to increase cell count.Reagent adopts the AneuVysion test kit of Abbott GmbH. & Co. Kg of Switzerland, complete 3 articles of chromosomal number analyses: No. 18 (Spectrum Aqua, cyan), X (Spectrum Green, green), Y (Spectrum Orange, red) number karyomit(e) is counting oligonucleotide (Chromosome Enumerating Probe, CEP), hybridization the 1st region after mixing, method gets 18, X and Y chromosome probe, by synchronous for Quality Control cell (sample tested with laboratory), through the centrifugal 10min of 2000r/min, remove supernatant, stay precipitation 0.2ml, 4ml collagenase 37 DEG C temperature bath 30min is added in centrifuge tube, the centrifugal 10min of 2000r/min, remove supernatant, then the 15mol/L KC1 of the pre-temperature of 5ml is added, hypotonic 25min in 37 water-baths, the centrifugal 10min of 2000r/min, remove supernatant.Add the fixing 10min of stationary liquid (methyl alcohol: Glacial acetic acid=3:1) of new preparation, centrifugal 2000r/min is centrifugal, and 10min removes supernatant, twice repeatedly.Drip sheet, seasoning is aging.Taken out in refrigerator-freezer by the sample slice prepared, put successively in people 70%, 85%, 100% ethanol and dewater, drying at room temperature, the slide that pre-treatment is good puts 73 DEG C, 5min in 70% methane amide.Two kinds of each 10 μ l of probe mixed solution are added in the target region of slide in darkroom, covered, avoid producing bubble, cover glass is sealed by mounting glue, put 42 DEG C of hybridized overnight in dark wet box, cleaning, at high power Microscopic observation crossbreeding effect, every routine sample counting 60 ~ 100 cells, record hybridization signal number also gathers image, require that nuclear membrane must be complete, hybridization signal zero lap limpid in sight in core, signal disperse and faintly all not take statistics.3. test result: after probe hybridization, the point of intracellular No. 18 karyomit(e)s display cyan, the point of No. 18, every bar display 1 cyan, 2 points then showing 2 cyans, 3 points then showing 3 cyans; The point that in cell, the display of X (women) karyomit(e) is green, every bar X chromosome shows 1 green point, 2 points that then display 2 is green, 3 points that then display 3 is green; The point that in cell, the display of Y (male sex) karyomit(e) is red, every bar Y chromosome shows 1 red point, 2 points that then display 2 is red, 3 points that then display 3 is red.If experimenter's technology, operation, experiment equipment, reagent etc. are defective in quality, then in the point of No. 21 karyomit(e) redness, cell, in the point of X (women) karyomit(e) green, cell, the point of Y (male sex) karyomit(e) redness does not just have signal or is difficult to recognize.4. in addition, case cell model can be used for the positive control of the technique of gene detection such as gene chip, miRNA chip, comparative genomic hybridization hybrid chip (CGH), differential methylation hybridization hybrid chip (DMH) and SNPs, Northern blot, Real-time PCR, CHIP, EMSA, or as case resource conservation, standby effect aforesaid method does the detections such as transgenation, genomics, proteomics, to analyze pathogeny.
Claims (7)
1. the hTERT transgenosis for medical field builds E trisomy cell model and cell bank thereof, its principal character is with restriction endonuclease EcoR I and Xho I double digestion plasmid pCIneo-hTERT and carrier pLXSNneo, connect through pcr amplification with LigationMix, hTERT and the pLXSNneo digestion products that gel electrophoresis is separated, build pLXSNneo-hTERT recon, transform DH5a competent cell with the purifying amplification also picking bacterium colony of resistance to penbritin extracting plasmid, to go down to posterity in vitro the E trisomy cell in logarithmic growth with liposome transfection, recon and cell DNA are integrated, and enlarged culturing is cloned containing positive recombinant through G418 screening, screening cellular form, growth curve, karyotype, nude mice tumorigenesis is tested, transfectional cell telomerase activation, hTERT mrna expression, immunohistochemical methods, cell generation cycle and apoptosis rate thereof meet immortality cell characteristic and identical with primary cell or close person mediates E trisomy as hTERT that to study cell model outward frozen in liquid nitrogen, for laying the foundation from cell levels (substituting human body or animal straightway testing) its pathogenesis that studies for a long period of time in vitro.
2. hTERT transgenosis according to claim 1 builds E trisomy cell model and cell bank thereof, it is characterized in that indication cell model be (1) cell be under inverted light microscope the epithelial cell sample adherent growth of fusiformis or little circular; (2) growth curve of cell is as taken incubation time as transverse axis, and cell quantity is the longitudinal axis, is that " S " feature or " arched roof " are formed in hepato ZYME-SFM serum free medium; (3) karyotype is 47, XX ,+18; Or 47, XY ,+18; (4) cell can not grow (forming clone) in soft agar; (5) cell is non-malign cells, nude mice tumorigenesis negative; (6) there is immortalization because incorporating hTERT gene in the DNA of cell, and express the mRNA product of hTERT; (7) passage to the 67th generation, be cultured to the 10th day time, in logarithmic growth, circle, fusiformis, to be paved with bottle at the bottom of, its Growth of Cells converges rate and reaches more than 93%; (8) can repeatedly freeze-thaw, Long Term Passages cultivate; (9) for studying the pathomechanism of Edwards syndrome; (10) genetic resources of 18 heterotrimeric cell that hTERT integrates is preserved on recyclability ground.
3. hTERT transgenosis according to claim 1 builds E trisomy cell model and cell bank thereof, it is characterized in that taking from gathers because other experiments are required and E trisomy infant amniotic fluid cast-off cells that are unnecessary after other experiments, that discard build it.
4. hTERT transgenosis according to claim 1 builds E trisomy cell model and cell bank thereof, it is characterized in that nutrient solution used is the RPMI1640 containing 20% foetal calf serum, 5 ~ 10nmol/L Regular Insulin or the low sugar DMEM nutrient solution containing 20mL/L foetal calf serum, 5 ~ 10nmol/L Regular Insulin.
5. hTERT transgenosis according to claim 1 builds E trisomy cell model and cell bank thereof, it is characterized in that being used as Secondary Culture imports recon E trisomy histocyte in order to lipofection, in primary amplification cultivation, its collect index be cell attachment cultivate about 3 ~ 4 days, cellular form is fusiformis, little circular cell less than 10%, the rate of converging of attached cell reaches 75% ~ 85%, is in collecting cell when just entering logarithmic phase; Import the E trisomy histocyte that goes down to posterity of recon as lipofection, the index of its choose opportunities is cellular form be fusiformis, there is not yet or be rarely seenly less than 10% little circular cell, the rate of converging of attached cell reaches 55% ~ 65%, is in culturing cell when entering or just entered logarithmic phase; The index that continuous cell line is collected be select cell attachment growth converge that rate reaches 80 ~ 85%, collecting cell when being in the early stage of logarithmic phase; The cell harvesting index of chromosome karyotype analysis is that cell density reaches 85-95%, little circular cell accounts for more than 10%, is in the cell of logarithmic phase.
6. hTERT transgenosis according to claim 1 builds E trisomy cell model and cell bank thereof, it is characterized in that the E trisomy histocyte digesting adherent growth with 0.01% collagenase II, when making chromosome karyotype analysis, add 250ug/ml colchicine 100ul in every 5mL nutrient solution, mix rearmounted 37 DEG C of incubators 4 hours.
7. hTERT transgenosis according to claim 1 builds E trisomy cell model and cell bank thereof, it is characterized in that the structure of cell bank comprises (1) screening and after qualification, meets immortalized cells characteristic and the E trisomy cell that mediates of the hTERT identical or close with primary cell; (2) go down to posterity, enlarged culturing, get the attached cell that growth conditions is good, be in the different generations of logarithmic phase; (3) through digestion, termination, centrifugal (1200r/min, 6min) step harvested cell; (4) preparing density with the frozen storing liquid containing methyl-sulphoxide is 5 × 10
5the cell suspension of individual/ml; (5) according to 4 DEG C, 0.5h;-20 DEG C, 2h;-70 DEG C, spend the night; Enter the program freeze-stored cell of-196 DEG C of liquid nitrogen; (6) the long-term hTERT of preservation in recyclability ground mediates E trisomy cell model, for making genetic resources and scientific research material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310407555.3A CN104419677A (en) | 2013-09-01 | 2013-09-01 | Construction of trisomy 18 syndrome cell model and cell bank thereof by hTERT transgenosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310407555.3A CN104419677A (en) | 2013-09-01 | 2013-09-01 | Construction of trisomy 18 syndrome cell model and cell bank thereof by hTERT transgenosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104419677A true CN104419677A (en) | 2015-03-18 |
Family
ID=52969801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310407555.3A Pending CN104419677A (en) | 2013-09-01 | 2013-09-01 | Construction of trisomy 18 syndrome cell model and cell bank thereof by hTERT transgenosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104419677A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112391461A (en) * | 2020-05-07 | 2021-02-23 | 苏州艾可瑞斯生物科技有限公司 | Trisomy syndrome gene nucleic acid detection quality control product based on CRSIPR-Cas9 and organoid culture and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1179581A (en) * | 1996-05-30 | 1998-04-22 | 松下电器产业株式会社 | Data converter for data communication system |
| CN101942413A (en) * | 2009-07-07 | 2011-01-12 | 翁炳焕 | Birth defect cell bank and construction method thereof |
-
2013
- 2013-09-01 CN CN201310407555.3A patent/CN104419677A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1179581A (en) * | 1996-05-30 | 1998-04-22 | 松下电器产业株式会社 | Data converter for data communication system |
| CN101942413A (en) * | 2009-07-07 | 2011-01-12 | 翁炳焕 | Birth defect cell bank and construction method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 汪廷乐等: "永生化细胞系模型建立的方法", 《上海口腔医学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112391461A (en) * | 2020-05-07 | 2021-02-23 | 苏州艾可瑞斯生物科技有限公司 | Trisomy syndrome gene nucleic acid detection quality control product based on CRSIPR-Cas9 and organoid culture and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101942413B (en) | Birth defect cell bank and construction method thereof | |
| CN110079501A (en) | Mouse breast cancer circulating tumor cell system and its method for building up | |
| CN104419676A (en) | Construction of down's syndrome cell model and cell bank of down's syndrome cell by employing hTERT gene recombination | |
| CN104419677A (en) | Construction of trisomy 18 syndrome cell model and cell bank thereof by hTERT transgenosis | |
| CN103667192B (en) | Atypical chronic myeloid leukemia cell line and preparation method thereof | |
| CN104419682A (en) | Construction of trisomy 21 syndrome cell model and cell bank thereof by using recombined SV40LT and hTERT genes | |
| CN104060329A (en) | Immortalized quality-control cell bank for chromosome karyotype analysis and construction method thereof | |
| CN104419684A (en) | Construction of 18-trisomy syndrome cell model and cell bank of 18-trisomy syndrome cell by SV40LT gene transfection | |
| CN109666643A (en) | One plant of cervical intraepithelial neoplasia (CIN) cell line and application thereof containing sequestered HPV18 | |
| CN104419727A (en) | Construction of neural tube defect cell model and cell bank thereof under induction of hTERT recombinant | |
| CN104419730A (en) | Construction of chromosome deficiency cri du chat syndrome cell model and cell bank of chromosome deficiency cri du chat syndrome cell model by employing hTERT transfection | |
| CN104419678A (en) | Method for constructing cell model and cell bank for Edward syndrome by mediation of hTERT (human Telomerase Reverse Transcriptase) and SV40LT recombinants | |
| CN104059882A (en) | Fluorescence in situ hybridization hTERT transfected external quality assessment cell line and preparation method thereof | |
| CN104419728A (en) | Establishment of cri du chat syndrome cell model and cell bank of cri du chat syndrome cell model through hTERT and SV40LT combined mediation | |
| CN120442527B (en) | Gekko Swinhonis kidney cells and establishment method and application thereof | |
| CN104419722A (en) | Construction of Turner syndrome cell model and cell bank of Turner syndrome cell by virtue of importing of hTERT | |
| CN104419673A (en) | Method for constructing cell model and cell bank for Klinefelter syndrome by transfecting hTERT (human Telomerase Reverse Transcriptase) recombinant gene | |
| CN104419666A (en) | Construction of chromosome translocation cell model and cell bank thereof by virtue of transfection of monkey kidney virus 40 capital T genes | |
| CN104419675A (en) | Establishment of congenital heart disease ventricular septal defect cell model by virtue of recombinant hTERT and cell bank of recombinant congenital heart disease ventricular septal defect cell model | |
| CN104419681A (en) | Construction of Turner syndrome cell model and cell bank of Turner syndrome cell by SV40LT and hTERT gene transduction | |
| CN104419663A (en) | Method for constructing cell model and cell bank for chromosomal translocation by recombination of hTERT (human Telomerase Reverse Transcriptase) | |
| CN104419679A (en) | Construction of Klinefelter's syndrome cell model and cell bank of Klinefelter's syndrome cell by hTERT and SV40LT gene induction | |
| CN104419674A (en) | Construction of atrial septal defect cell model of congenital heart disease by virtue of hTERT induction and cell bank of atrial septal defect cell model | |
| CN104419665A (en) | SV40LT-mediated down syndrome cell model and construction method of cell bank thereof | |
| CN104419662A (en) | Building of atrial septal defect cell model and cell bank of atrial septal defect cell model by employing SV40LT and hTERT gene transfection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150318 |
|
| RJ01 | Rejection of invention patent application after publication |